Drug Profile
813893
Alternative Names: GSK-813893Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antithrombotics
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 20 Apr 2011 Discontinued - Phase-I for Stroke in United Kingdom (unspecified route)
- 25 Jan 2008 Phase-I development is ongoing
- 06 Dec 2004 Phase-I clinical trials in Stroke in United Kingdom (unspecified route)